Delisting risk
Psyence Biomedical (PBM)
Developing nature-derived psilocybin-assisted psychotherapy for adjustment disorder after cancer.
$4.27
Pre-market−0.14 (−3.06%)
At close$4.41(+0.80%)
Something off on this page? Send us feedback.
EPSReportedEstimate
——————FY21FY22
Reported——————−$0.27$0.17
Estimate————————
Surprise————————
RevenueReportedEstimate
——————FY21FY22
Reported——————$0$0
Estimate————————
Surprise————————
History
| Fiscal year | Estimate | Reported | Surprise |
|---|---|---|---|
| 2022 | — | $0.17 | — |
The latest year is open to everyone — the 1 fiscal year behind it read with an account. Sign in | |||
| 2021 | |||
| Fiscal year | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| 2022 | — | $0.17 | — | — | $0 | — |
The latest year is open to everyone — the 1 fiscal year behind it read with an account. Sign in | ||||||
| 2021 | ||||||